|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 4179 |
FusionGeneSummary for BIRC2_TTC17 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: BIRC2_TTC17 | Fusion gene ID: 4179 | Hgene | Tgene | Gene symbol | BIRC2 | TTC17 | Gene ID | 329 | 55761 |
| Gene name | baculoviral IAP repeat containing 2 | tetratricopeptide repeat domain 17 | |
| Synonyms | API1|HIAP2|Hiap-2|MIHB|RNF48|c-IAP1|cIAP1 | - | |
| Cytomap | 11q22.2 | 11p12-p11.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | baculoviral IAP repeat-containing protein 2IAP homolog BIAP-2NFR2-TRAF signalling complex proteinRING finger protein 48RING-type E3 ubiquitin transferase BIRC2TNFR2-TRAF-signaling complex protein 2apoptosis inhibitor 1cellular inhibitor of apoptos | tetratricopeptide repeat protein 17TPR repeat protein 17 | |
| Modification date | 20180523 | 20180523 | |
| UniProtAcc | Q13490 | Q96AE7 | |
| Ensembl transtripts involved in fusion gene | ENST00000530675, ENST00000227758, ENST00000532672, ENST00000527910, | ENST00000299240, ENST00000039989, ENST00000526774, | |
| Fusion gene scores | * DoF score | 3 X 3 X 3=27 | 4 X 4 X 3=48 |
| # samples | 3 | 4 | |
| ** MAII score | log2(3/27*10)=0.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(4/48*10)=-0.263034405833794 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: BIRC2 [Title/Abstract] AND TTC17 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | BIRC2 | GO:0000209 | protein polyubiquitination | 11907583 |
| Hgene | BIRC2 | GO:0043066 | negative regulation of apoptotic process | 21525013 |
| Hgene | BIRC2 | GO:0043161 | proteasome-mediated ubiquitin-dependent protein catabolic process | 11907583 |
| Hgene | BIRC2 | GO:0051726 | regulation of cell cycle | 15665297 |
| Hgene | BIRC2 | GO:1902523 | positive regulation of protein K63-linked ubiquitination | 21931591 |
| Hgene | BIRC2 | GO:1902524 | positive regulation of protein K48-linked ubiquitination | 21931591 |
| Hgene | BIRC2 | GO:1902527 | positive regulation of protein monoubiquitination | 21931591 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS3.1 | AF207599 | BIRC2 | chr11 | 102248448 | + | TTC17 | chr11 | 43514845 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5CDS-intron | ENST00000530675 | ENST00000299240 | BIRC2 | chr11 | 102248448 | + | TTC17 | chr11 | 43514845 | + |
| 5CDS-intron | ENST00000530675 | ENST00000039989 | BIRC2 | chr11 | 102248448 | + | TTC17 | chr11 | 43514845 | + |
| 5CDS-intron | ENST00000530675 | ENST00000526774 | BIRC2 | chr11 | 102248448 | + | TTC17 | chr11 | 43514845 | + |
| 5CDS-intron | ENST00000227758 | ENST00000299240 | BIRC2 | chr11 | 102248448 | + | TTC17 | chr11 | 43514845 | + |
| 5CDS-intron | ENST00000227758 | ENST00000039989 | BIRC2 | chr11 | 102248448 | + | TTC17 | chr11 | 43514845 | + |
| 5CDS-intron | ENST00000227758 | ENST00000526774 | BIRC2 | chr11 | 102248448 | + | TTC17 | chr11 | 43514845 | + |
| 5CDS-intron | ENST00000532672 | ENST00000299240 | BIRC2 | chr11 | 102248448 | + | TTC17 | chr11 | 43514845 | + |
| 5CDS-intron | ENST00000532672 | ENST00000039989 | BIRC2 | chr11 | 102248448 | + | TTC17 | chr11 | 43514845 | + |
| 5CDS-intron | ENST00000532672 | ENST00000526774 | BIRC2 | chr11 | 102248448 | + | TTC17 | chr11 | 43514845 | + |
| 3UTR-intron | ENST00000527910 | ENST00000299240 | BIRC2 | chr11 | 102248448 | + | TTC17 | chr11 | 43514845 | + |
| 3UTR-intron | ENST00000527910 | ENST00000039989 | BIRC2 | chr11 | 102248448 | + | TTC17 | chr11 | 43514845 | + |
| 3UTR-intron | ENST00000527910 | ENST00000526774 | BIRC2 | chr11 | 102248448 | + | TTC17 | chr11 | 43514845 | + |
Top |
FusionProtFeatures for BIRC2_TTC17 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| BIRC2 | TTC17 |
| Multi-functional protein which regulates not onlycaspases and apoptosis, but also modulates inflammatory signalingand immunity, mitogenic kinase signaling, and cell proliferation,as well as cell invasion and metastasis. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and regulates bothcanonical and non-canonical NF-kappa-B signaling by acting inopposite directions: acts as a positive regulator of the canonicalpathway and suppresses constitutive activation of non-canonicalNF-kappa-B signaling. The target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4,CASP3, CASP7, CASP8, TRAF2, DIABLO/SMAC, MAP3K14/NIK, MAP3K5/ASK1,IKBKG/NEMO, IKBKE and MXD1/MAD1. Can also function as an E3ubiquitin-protein ligase of the NEDD8 conjugation pathway,targeting effector caspases for neddylation and inactivation. Actsas an important regulator of innate immune signaling viaregulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs)and RIG-I like receptors (RLRs), collectively referred to aspattern recognition receptors (PRRs). Protects cells fromspontaneous formation of the ripoptosome, a large multi-proteincomplex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosomeformation by ubiquitinating RIPK1 and CASP8. Can stimulate thetranscriptional activity of E2F1. Plays a role in the modulationof the cell cycle. {ECO:0000269|PubMed:15665297,ECO:0000269|PubMed:18082613, ECO:0000269|PubMed:21145488,ECO:0000269|PubMed:21653699, ECO:0000269|PubMed:21931591,ECO:0000269|PubMed:23453969}. | Plays a role in primary ciliogenesis by modulating actinpolymerization. {ECO:0000269|PubMed:24475127}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for BIRC2_TTC17 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for BIRC2_TTC17 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for BIRC2_TTC17 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for BIRC2_TTC17 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | BIRC2 | C0019693 | HIV Infections | 1 | CTD_human |
| Hgene | BIRC2 | C0023418 | leukemia | 1 | CTD_human |
| Hgene | BIRC2 | C0038356 | Stomach Neoplasms | 1 | CTD_human |
| Hgene | BIRC2 | C1458155 | Mammary Neoplasms | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|